Cancer Biology

In depth profiling of the cancer proteome from the flowthrough of standard RNA- preparation kits for precision oncology

1. Filip Mundt Madsen
2. Annelaura Bach Nielsen
3. Juanjuan Wang
4. Josephine Kerzel Duel
5. Christina Westmose Yde
6. Martina Amnitzbøll Eriksen
7. Ulrik Lassen
8. Finn Cilius Nielsen
9. Kristoffer Rohrberg
10. Matthias Mann

Reviewed by preLights

Targeting a novel chloroquine derivative to lysosomes induces massive and irreversible damage to lysosomes and suppresses autophagosomes and lysosomes assembly in cancer

1. Nitish Chauhan
2. Ananda Guha Majumdar
3. Sujit Kumar Bhutia
4. Papiya Dey
5. Mahesh Subramanian
6. Birija Sankar Patro

Reviewed by Arcadia Science

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

1. Sander Frank
2. Thomas Persse
3. Ilsa Coleman
4. Armand Bankhead
5. Dapei Li
6. Navonil De-Sarkar
7. Divin Wilson
8. Dmytro Rudoy
9. Manasvita Vashisth
10. Patty Galipeau
11. Michael Yang
12. Brian Hanratty
13. Ruth Dumpit
14. Colm Morrissey
15. Eva Corey
16. R Bruce Montgomery
17. Michael C Haffner
18. Colin C Pritchard
19. Valeri Vasioukhin
20. Gavin Ha
21. Peter S Nelson

• Curated by eLife

  eLife Assessment

  The paper is a fundamental study examining the role of CDK12 loss in prostate cancer. While previous studies have suggested that CDK12 loss confers HRD phenotypes, clinical trials using PARPi in CDK12 altered patients have not demonstrated significant benefit. This work investigates these mechanisms in depth and provides compelling evidence. A comprehensive genomic analysis serves an excellent resource to the field, showing that biallelic CDK12 alterations do not have genomic features of HRd. Moreover, the study explored both acute and chronic deletion of CDK12, with data suggestive of CDK12-altered cells being uniquely sensitive to CDK13 inhibition. While some minor weaknesses have been previously noted by the reviewers, the authors have adequately addressed these concerns with appropriate rigor.

Reviewed by eLife

Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments

1. Adèle Delamarre
2. Marie Decraecker
3. Jean-Frédéric Blanc
4. Sylvaine Di Tommaso
5. Cyril Dourthe
6. Jean-William Dupuy
7. Mélanie Moreau
8. Nathalie Allain
9. Isabelle Mahouche
10. Julie Giraud
11. Giovanni Bénard
12. Claude Lalou
13. Benoît Pinson
14. Paulette Bioulac-Sage
15. Caroline Toulouse
16. Audrey Morisset
17. Jérôme Boursier
18. Brigitte Le Bail
19. Anne-Aurélie Raymond
20. Frédéric Saltel

Reviewed by PREreview